Chemomab Therapeutics Ltd
NASDAQ:CMMB
Chemomab Therapeutics Ltd
EPS (Diluted)
Chemomab Therapeutics Ltd
EPS (Diluted) Peer Comparison
Competitive EPS (Diluted) Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Chemomab Therapeutics Ltd
NASDAQ:CMMB
|
EPS (Diluted)
-$2
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
EPS (Diluted)
$0
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
EPS (Diluted)
$0
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
EPS (Diluted)
-$3
|
CAGR 3-Years
16%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
EPS (Diluted)
$0
|
CAGR 3-Years
20%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
EPS (Diluted)
₪0
|
CAGR 3-Years
-96%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
-10%
|
See Also
What is Chemomab Therapeutics Ltd's EPS (Diluted)?
EPS (Diluted)
-2.1
USD
Based on the financial report for Dec 31, 2023, Chemomab Therapeutics Ltd's EPS (Diluted) amounts to -2.1 USD.
What is Chemomab Therapeutics Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
26%
Over the last year, the EPS (Diluted) growth was -6%. The average annual EPS (Diluted) growth rates for Chemomab Therapeutics Ltd have been 26% over the past three years .